Audrey Vega, MD
Family Medicine · Roswell, NMNPI 1659368256
Payments from drug & device makers
Across 92 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$244
- Amgen$124
- AstraZeneca$119
- Lilly USA, LLC$106
- Mylan Specialty L.p.$105
- Sanofi-aventis U.S. LLC$83
- plus $744 from 18 others
What the payments were for
- Food & beverage$1,50298%
- Education$232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 14 | $244 |
| Amgen | 7 | $124 |
| AstraZeneca | 8 | $119 |
| Lilly USA, LLC | 7 | $106 |
| Mylan Specialty L.p. | 5 | $105 |
| Sanofi-aventis U.S. LLC | 5 | $83 |
| Amarin Pharma, Inc. | 5 | $82 |
| AbbVie(2 entities) | 5 | $80 |
| Merck | 4 | $60 |
| Astellas Pharma US Inc | 4 | $58 |
| Johnson & Johnson | 3 | $54 |
| GSK | 3 | $53 |
| Radius Health, Inc. | 2 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Boehringer Ingelheim | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Novo Nordisk | 2 | $29 |
| Novartis | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $14 |
How this compares
$1,525 in reported general payments places this provider in the 85th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 93 | $154,696 |
| EliquisApixaban | 64 | $62,465 |
| OzempicSemaglutide | 68 | $61,564 |
| Wellbutrin XlBupropion Hcl | 12 | $60,747 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $34,858 |
| JanuviaSitagliptin Phosphate | 27 | $34,821 |
| ProliaDenosumab | 15 | $26,013 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $24,607 |
| GlyxambiEmpagliflozin/Linagliptin | 17 | $23,196 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $23,069 |
| TrulicityDulaglutide | 22 | $21,411 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $20,498 |
| MyrbetriqMirabegron | 27 | $17,695 |
| FarxigaDapagliflozin Propanediol | 19 | $16,599 |
| Spiriva RespimatTiotropium Bromide | 13 | $15,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $106 | $176,106115 claims |
| PfizerEliquis | $244 | $62,46564 claims |
| Novo NordiskOzempic | $29 | $61,56468 claims |
| Boehringer IngelheimGlyxambi, Spiriva Respimat, Combivent Respimat | $34 | $44,22642 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $119 | $37,09740 claims |
| MerckJanuvia | $60 | $34,82127 claims |
| AmgenProlia | $124 | $26,01315 claims |
| GSKTrelegy Ellipta | $53 | $23,06930 claims |
| Astellas Pharma US IncMyrbetriq | $58 | $17,69527 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $40 | $11,98317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Roswell
- Richard PinonRoswell$4K
- Brandon ComettiRoswell$3K
- Quito CarrAlbuquerque$10.4M
- Satkirin KhalsaAlbuquerque$5.8M
- Ellen KimAlbuquerque$2.2M
- Sally FisherAlbuquerque$1.8M
- Wendy JohnsonSanta Fe$270K
- Harold McFarlingFarmington$160K
- Effat BanikarimAlamogordo$86K
- Jeanne-Elyse CedenoLos Lunas$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.